Oncology Aids Pfizer As Biosimilars Track To $1bn In 2020

Upjohn Separation In Progress Ahead Of Mylan Merger

 
• By Dean Rudge

Pfizer is on course for a major milestone for biosimilars this year, as it continues to make plans for the separation of its off-patent and mature brands unit, Upjohn, ahead of its merger with Mylan.

Billion
Pfizer is well on course to push $1bn in sales this year, bettering the $911m achieved in 2019 • Source: Shutterstock

More from Earnings

More from Business